Home Aktuelles DRFZ vs SARS-CoV-2

DRFZ vs SARS-CoV-2

Tracking immunity to the novel coronavirus

Regarding antibody-producing plasma cells and B lymphocytes, innate lymphocytes, T lymphocytes and immunological memory, i.e. long-term immunity, the DRFZ is one of the world’s leading research institutes. Here, unique technologies for unraveling the mechanisms behind immune reactions have been developed. This expertise is now used to look into SARS-CoV2 immunity and immunopathology, in collaboration with the virological department and clinical research groups from the Charité Universitätsmedizin Berlin.

Scientists from the program area Epidemiology participate in the development of national and international data collections and registers in order to investigate the specific risk of a severe course of COVID-19 disease for of patients with various rheumatic diseases.